Humana Inc. (NYSE:HUM) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

Several other equities research analysts have also issued reports on HUM. UBS AG reaffirmed a “neutral” rating and issued a $237.00 price objective (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $257.00 price objective on shares of Humana in a research note on Friday, August 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $223.00 price objective (up previously from $200.00) on shares of Humana in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Humana from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $214.00 price objective on shares of Humana in a research note on Monday, June 5th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $244.35.

Humana (NYSE:HUM) traded down 0.15% on Thursday, reaching $247.28. The company’s stock had a trading volume of 754,398 shares. The stock has a 50 day moving average price of $241.05 and a 200-day moving average price of $224.57. The company has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. Humana has a 1-year low of $163.50 and a 1-year high of $255.27.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the previous year, the company posted $2.30 EPS. Equities analysts predict that Humana will post $11.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/20/bidaskclub-downgrades-humana-inc-hum-to-sell.html.

In other news, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the transaction, the vice president now owns 8,150 shares in the company, valued at approximately $1,890,474. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,406 shares of company stock worth $10,355,086. Insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. WFG Advisors LP increased its position in Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after buying an additional 20 shares during the last quarter. Guardian Life Insurance Co. of America increased its position in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the last quarter. Acrospire Investment Management LLC bought a new position in Humana during the second quarter valued at about $120,000. Independent Portfolio Consultants Inc. increased its position in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares during the last quarter. Finally, Point72 Asia Hong Kong Ltd bought a new position in Humana during the first quarter valued at about $128,000. Institutional investors own 99.13% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.